DUH... can it be...
that the CIBC expert has been less than objective in his negative appraisals? Could be!
(Just as I have said previously, btw.)
But looks like Jeffries has a few independent experts of their own:
"Both Jefco's physician experts believe that the CyberKnife is technologically superior to all of the competing radiation therapy platforms, including Varian's (NYSE: VAR) Trilogy, BrainLab's Novalis, Elekta's Synergy and Axesse, and TomoTherapy's (Nasdaq: TTPY) Hi-Art Systems."
So now it is "them" against the CIBC fellow... and best I recall, he ain't no physician!
Maybe NOW the PPS will begin to return to the 25-30 range that currently strikes me as justified.
JMO...